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OBJECTIVE — To determine whether systemic inﬂammation after initiation of HIV-
antiretroviral therapy (ART) is associated with the development of diabetes.
RESEARCH DESIGN AND METHODS — We conducted a nested case-control study,
comparing 55 previously ART-naive individuals who developed diabetes 48 weeks after ART
initiation (case subjects) with 55 individuals who did not develop diabetes during a comparable
follow-up (control subjects), matched on baseline BMI and race/ethnicity. Stored plasma sam-
ples at treatment initiation (week 0) and 1 year later (week 48) were assayed for levels of
high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), and the soluble receptors of
tumor necrosis factor- (sTNFR1 and sTNFR2).
RESULTS — Case subjects were older than control subjects (median age 41 vs. 37 years, P 
0.001),butthegroupswereotherwisecomparable.Medianlevelsforallmarkers,excepths-CRP,
decreasedfromweek0toweek48.Subjectswithhigherlevelsofhs-CRP,sTNFR1,andsTNFR2
at 48 weeks had an increased odds of subsequent diabetes, after adjustment for baseline marker
level,age,BMIatweek48,CD4countatweek48(vs.200cells/mm
3),andindinaviruse(all
Ptrend  0.05). After further adjustment for week 48 glucose, effects were attenuated and only
sTNFR1 remained signiﬁcant (odds ratio, highest quartile vs. lowest 23.2 [95% CI 1.28–423],
P  0.03).
CONCLUSIONS — Inﬂammatory markers 48 weeks after ART initiation were associated
with increased risk of diabetes. These ﬁndings suggest that systemic inﬂammation may contrib-
ute to diabetes pathogenesis among HIV-infected patients.
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W
iththeadventofeffectiveantiret-
roviral therapy (ART), morbidity
and mortality have decreased
dramatically among HIV-infected pa-
tients and the proportion of older HIV-
infected patients is rising. As a result,
aging-related comorbidities, such as dia-
betes, have become increasingly impor-
tant in the management of HIV-infected
patients.
Abnormalities in glucose metabolism
occur commonly in HIV-infected pa-
tients, and some cohorts have shown a
higher than expected risk of insulin resis-
tanceanddiabetescomparedwiththatfor
HIV-negative control populations (1,2).
The etiology is multifactorial. Certain
protease inhibitors, such as indinavir
(IDV), lopinavir, and ritonavir, have been
shown to reversibly induce insulin resis-
tance, probably by inhibition of glucose
translocation through GLUT4 (3). The
nucleoside reverse transcriptase inhibi-
tors, zidovudine and stavudine, also have
direct and indirect effects on glucose me-
tabolism (4,5). Chronic infection with
HIV may also contribute to glucose ab-
normalities among HIV-infected patients.
IntheMulticenterAIDSCohortStudy,in-
sulinresistancemarkerswerehigherinall
groups of HIV-infected men compared
with HIV-uninfected control subjects,
evenamongthosewhowerenotreceiving
ART (6), suggesting an effect of HIV in-
fection itself.
Systemicinﬂammationhasbeenasso-
ciated with incident diabetes in multiple
cohorts in the general population (7–9).
Proinﬂammatory cytokines, such as tu-
mor necrosis factor (TNF)-, may induce
insulin resistance by binding to insulin-
responsive elements in skeletal muscle
(10). Among HIV-infected patients,
markers of systemic inﬂammation de-
crease quickly with ART initiation (11)
butdonotnormalize(12).Itisspeculated
thatthisresidualinﬂammationwitheffec-
tive ART may contribute to the pathogen-
esis of comorbidities in HIV-infected
patients, including diabetes (13). We un-
dertook a case-control study, nested
withinanobservationalstudyoftheAIDS
ClinicalTrialGroup(ACTG)todetermine
whether markers of systemic inﬂamma-
tion measured 48 weeks after ART ini-
tiation were associated with the develop-
ment of diabetes.
RESEARCH DESIGN AND
METHODS— The ACTG Longitudi-
nal Linked Randomized Trials (ALLRT)
cohort was designed to enroll HIV-
infected individuals previously random-
ized into approved parent ACTG clinical
trials (parent studies) for the purpose of
evaluating clinical, virological, immuno-
logical, metabolic, and pharmacological
outcomes associated with long-term
treatment with potent ARTs. Individuals
could be treatment-naive or treatment-
experienced at entry into their parent
study. Enrollment into ALLRT began in
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viduals were enrolled into ALLRT. All
subjects provided written informed con-
sent, and each ACTG study site received
approval from the designated institu-
tional review board before protocol initi-
ation. Details of the ALLRT protocol have
been described previously (14).
The eligible population for this pro-
spective, nested case-control study in-
cluded all HIV-infected individuals from
treatment-naive parent studies co-
enrolled in ALLRT, with the exception of
parent studies for which ART data were
still blinded. Eligible individuals were re-
quired to have had fasting or nonfasting
blood glucose measurements before and
after ART initiation and during the fol-
low-up period, as well as plasma samples
taken at the time of treatment initiation
and at week 48, for measurement of in-
ﬂammatory markers. We used data sub-
mitted to our data management center as
of October 2008.
Allpotentialcaseorcontrolsubjects
were required to have fasting or non-
fastingbloodglucoselevels100mg/dl
at the time of treatment initiation (base-
line) or within 16 weeks after initiation
and could not have a history of hypo-
glycemicmedicationuseordiabetes.All
individuals who developed diabetes 1
years after ART initiation were eligible
to be included as case subjects. Control
subjects (non–case subjects) were ran-
domly selected from those individuals
who did not develop diabetes and who
maintained fasting blood glucose levels
100 mg/dl through the study period.
Control subjects were matched to case
subjects 1:1 by BMI at treatment initia-
tion and by race/ethnicity. Control sub-
jects were followed for at least as long as
their matched case subject. The glucose
and medication histories of each of
these case subjects and control subjects
were reviewed by hand by an endocri-
nologist (T.T.B.) to conﬁrm their case
and control status.
Laboratory methods
After identiﬁcation of case subjects and
controlsubjects,frozenplasmasamplesat
weeks 0 and 48 were pulled from the re-
pository at the same time and forwarded
to the Johns Hopkins Bayview Advanced
Chemistry Laboratory (Baltimore, MD).
Markers were measured in duplicate us-
ing commercially available enzyme-
labeled immunosorbent sandwich assays,
and values were averaged for analysis.
The intra-assay precision of these assays
rangefrom4.4to7.6%coefﬁcientofvari-
ation (average 5.6% coefﬁcient of varia-
tion). The sensitivity of this assay system
for these cytokines ranged from 0.5 to 16
pg/ml. C-reactive protein was measured
using a highly sensitive ELISA (ALPCO
Diagnostics, Windham, NH). The linear
range of the assay standards is 0.0019–
0.15 mg/l, and samples with values
greater than the highest standard were di-
luted and reanalyzed.
Measures
Outcome. An incident case of diabetes
was deﬁned as having either two fasting
blood glucose levels 126 mg/dl (or two
consecutivenonfastingbloodglucoselev-
els200mg/dl)oradiagnosisofdiabetes
recorded in the medical record. The ﬁrst
high glucose level and the diagnosis date
had to occur at least 1 year after ART
initiation.
Inﬂammatory markers. Week 48 levels
of high-sensitivity (hs-CRP), interleukin
(IL)-6, and the soluble receptors of tumor
necrosis factor- (sTNFR1 and sTNFR2)
were each grouped into quartiles. Base-
line levels of each marker were natural
log-transformed.
In addition to the matching factors
BMI at baseline and race/ethnicity (white
non-Hispanic, black non-Hispanic, and
Hispanic), we considered several other
potential confounding variables: glucose
levels at week 48 (continuous), age (con-
tinuous), sex, calendar year of treatment
initiation,smokingstatus(everyesorno),
personal and family history of any cardio-
vascular disease, speciﬁc antiretroviral
regimens taken through week 48 (in par-





3 at weeks 0 and 48,
HIV-1 RNA 100,000 copies/ml at base-
line, HIV-1 RNA 400 copies/ml at week
48,BMIatweek48(continuous),andhis-
tory of hepatitis C infection.
Statistical analysis
Demographic, health, and treatment
characteristics were summarized and
comparedbetweencasesubjectsandcon-
trol subjects. P values from univariate
conditional logistic regression models
wereusedforstatisticalcomparisonsofall
covariates by case status with the excep-
tionofrace/ethnicity,whichwasamatch-
ing factor. Differences in marker levels at
baseline and at week 48 were also sum-
marized and compared using the Wil-
coxon signed-rank test.
Conditional logistic regression was
used to model the association between
week 48 levels of each inﬂammatory
marker and diabetes incidence, taking
into account matching and adjusting for
theotherpotentialconfounders.Thelow-
est marker quartile was the reference cat-
egory in each model. Each model
included categories of week 48 marker
quartile,naturallog-transformedbaseline
markerlevelandage.Modelbuildingpro-
ceeded by adding, one at a time, univari-
ate predictors of diabetes (P  0.10). P 
0.05 was considered statistically signiﬁ-
cant. Variables that changed odds ratios
by 15% were kept in the model as po-
tentialconfounders.Toassesstrendindi-
abetes incidence over marker quartiles,
quartiles for each marker were included
in the model as ordinal variables. Because
ofconcernthathyperglycemiainthenon-
diabetic range may lead to inﬂammation,
we reevaluated each model after adjust-
ment for glucose values at 48 weeks. In
these models, a variable indicating
whether the glucose determination was
made in the fasting state (yes or no) was
also included.
RESULTS— Of the 3,405 individuals
from the treatment-naive studies enrolled
as of October 2008, 1,217 were from par-
ent studies with ART data still blinded
and therefore were not eligible for this
analysis. Of the 2,188 remaining individ-
uals, 2,161 (99%) had fasting or nonfast-
ing glucose values within 16 weeks of
ART initiation, and 231 (10.7%) had glu-
cose values between 100 and 125 mg/dl
pretreatmentandwereexcluded.Another
63 individuals had either a prevalent di-
agnosis of diabetes, hypoglycemic medi-
cation use, fasting blood glucose 126
mg/dl, or nonfasting blood glucose 200
mg/dl at baseline and were also excluded.
Fromthisat-riskgroupof1,867,55cases
of incident diabetes (deﬁned as occurring
at least 1 year after ART initiation) were
identiﬁed. An additional 22 individuals
developed diabetes within the 1st year of
ART initiation and were not included in
analyses. Twenty-seven case subjects
(49%)wereidentiﬁedthrough2fasting
glucose values 126 mg/dl, with no clin-
icaldiagnosisormedicationuserecorded.
Twenty-four (44%) had elevated fasting
glucose and either a clinical diagnosis or
medication use, and the remainder (7%)
had a clinical diagnosis with or without
medication use reported, but no elevated
glucose. All case subjects with high glu-
cosehadhighfastingglucoselevels.Fifty-
Brown and Associates
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For 90% of case-control pairs the differ-
ence in BMI was 1 kg/m
2; ﬁve pairs dif-
fered by a greater amount (range 1.7–6.5
kg/m
2).
The median time to diabetes inci-
dence after week 48 was 1.9 years (inter-
quartile range 1.3–3.8 years). In Table 1,
we summarize demographic, treatment,
and health characteristics for case and
control subjects. Case subjects were sig-
niﬁcantlyolderthancontrolsubjects(me-
dian41vs.37years,P0.01).Therewas
no difference by case status in calendar
year of treatment initiation. Approxi-
mately 50% of each group had HIV RNA
levels 100,000 copies/ml at baseline,
and a greater proportion of case subjects
than control subjects had CD4 counts
200 cells/mm
3 at baseline. A higher
proportion of case subjects versus control
subjects had some use of IDV through
week 48 (16 vs. 6%, P  0.08).
Case subjects had signiﬁcantly higher
glucoselevelsatweek48thandidcontrol
subjects. Seventy-ﬁve individuals (40
casesubjectsand35controlsubjects)had
fastingglucoselevelsatorbeforeweek48,
and 35 individuals (15 case subjects and
20 control subjects) had only nonfasting
glucose levels. Median fasting levels for
case subjects and control subjects were
102 and 83 mg/dl, respectively (P value
0.001); median nonfasting values were
89 and 81 mg/dl, respectively (P value 
0.08).
Case subjects tended to have higher
baseline levels of inﬂammatory markers
than control subjects (Table 1), adding
furtherjustiﬁcationforincludingbaseline
marker levels in each multivariate model.
These baseline levels were not signiﬁ-
cantly associated with diabetes after ad-
justment for age (data not shown). In
Table 2, we present the median values of
each marker at baseline and week 48. hs-
CRP signiﬁcantly increased from week 0
to 48; all other markers decreased signif-
icantly from week 0 to 48.
Figure 1 summarizes the odds ratios
for the association of each inﬂammatory
marker at week 48 with subsequent dia-
betes incidence, adjusted for age, log of
baseline marker value, CD4 at week 48,
BMI at week 48, and IDV use through
week 48. Higher hs-CRP, sTNFR1, and
sTNFR2 levels, but not IL-6 levels, 1 year
after ART initiation were all signiﬁcantly
associated with diabetes incidence before
adjustment for glucose level at week 48.
After additional adjustment for week 48
glucose, only sTNFR1 remained signiﬁ-
cantly associated with diabetes incidence
(Table 3).
Six individuals (ﬁve case subjects
and one control subject) had not
reached viral suppression by week 48.
In a sensitivity analysis that excluded
these six individuals and their matched
case/control subject, the results were
relatively unchanged. For sTNFR1 the
associationbetweenthehighestquartile
Table 1—Baseline and on-treatment characteristics of case and control subjects
Covariate Case subjects Control subjects P value*
n 55 55
Sex
Male 42 (76) 42 (76) 1.00
Female 13 (24) 13 (24)
Age in years at week 0 41 (37–46) 37 (31–42) 0.001
Race/ethnicity
White 26 (47) 26 (47)
African American 13 (24) 13 (24) —†
Hispanic 16 (29) 16 (29)
BMI at week 0 (kg/m
2) 25.1 (22.7–30.0) 25.1 (22.7–29.8) 0.14
BMI at week 48 (kg/m
2) 28.1 (24.7–33.1) 27.6 (24.1–30.4) 0.01
hs-CRP at week 0 (mg/l) 2.41 (1.36–4.37) 1.57 (0.85–4.33) 0.07
IL-6 at week 0 (pg/ml) 1.74 (1.16–2.95) 1.32 (0.80–2.52) 0.08
TNFR1 at week 0 (pg/ml) 1,386 (1,132–1,725) 1,213 (1,081–1,470) 0.03
TNFR2 at week 0 (pg/ml) 4,741 (3,292–6,950) 4,298 (3,646–5,185) 0.14
Glucose at/before week 48 (mg/dl)
Fasting (n  40 case subjects;
n  35 control subjects) 102 (91–111) 83 (80–89) 0.001
Nonfasting (n  15 case subjects;
n  20 control subjects) 89 (81–97) 81 (76–87)
0.08
0.001‡
Family history of CVD
Yes 11 (20) 6 (11) 0.18
Smoking status
Ever 28 (51) 29 (53) 0.84
Calendar year of treatment initiation
1998–1999 20 (36) 24 (44)
2001–2002 (none in 2000) 22 (40) 19 (34)
2003–2004 13 (24) 12 (22) 0.69
Hepatitis C
Ever 5 (9) 4 (8) 0.74
HIV RNA 100,000 copies/ml
at week 0
Yes 32 (58) 30 (55) 0.67
HIV RNA 400 copies/ml at
week 48
Yes 5 (9) 1 (2) 0.14
CD4 200 cells/mm
3 at week 0
Yes 36 (66) 23 (42) 0.02
CD4 200 cells/mm
3 at week 48
Yes 8 (15) 4 (7) 0.14
ART in ﬁrst 48 weeks
Any stavudine 19 (35) 14 (26) 0.32
Any zidovudine 43 (78) 37 (67) 0.19
Any nelﬁnavir 12 (22) 17 (31) 0.26
Any IDV 9 (16) 3 (6) 0.08
Any lopinavir/ritonavir 7 (13) 8 (15) 0.76
Dataaremedian(interquartilerange)orn(%).N110.*Fromunivariateconditionallogisticmodel,unless
otherwise indicated. †Matching factor. ‡From a univariate conditional logistic model (continuous glucose
term in model along with fasting status indicator).
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ated and for sTNFR2 the association be-
tweenthehighestquartileandthelowest)
was stronger (data not shown).
CONCLUSIONS — In this case-con-
trol study nested within a multicenter,
observational cohort of HIV-infected in-
dividuals receiving ART, we found that,
despite a decrease in most inﬂammatory
markers with ART initiation, markers of
TNF- activation 48 weeks after treat-
mentwereassociatedwithincidentdiabe-
tes. After further adjustment for glucose
levels at 48 weeks, the associations were
attenuated, but higher levels of sTNFR1
remained a signiﬁcant predictor of inci-
dent diabetes in adjusted analyses.
TNF- is an proinﬂammatory cyto-
kine produced by multiple cell types in-
cluding macrophages, lymphocytes, and
endothelial cells that contributes to the
inﬂammatory cascade (15) and is highly
expressed in both treated and untreated
HIV-infected patients (12,13). TNF- is
also produced by adipose tissue and has
been shown to interact with the insulin
receptor substrate to attenuate the effect
of insulin binding to its receptor (10). As
a result, TNF- has been proposed as a
mediating factor between adiposity and
insulin resistance. Blockers of TNF-,
however, such as inﬂiximab and etaner-
cept,haveshownconﬂictingeffectsonin-
sulin resistance in human populations
(16,17).
In epidemiological studies, the asso-
ciation between incident diabetes and
TNF activity, either measured by concen-
trations of the soluble receptors to TNF-
or by TNF- itself, has also been incon-
sistent.Inseveralstudies,sTNFR2wasas-
Figure1—Oddsratios(95%CI)forincidentdiabetesinHIV-infectedindividualsbyquartile(Q)ofhs-CRP(A),IL-6(B),sTNFR1(C),andsTNFR2
(D) measured 48 weeks after initiation of antiretroviral therapy, adjusted for baseline marker level, age, CD4 200 cells/mm
3 at week 48, 48-week
BMI, and use of IDV.
Table 2—Marker levels at week 0 and week 48 after initiation of antiretroviral therapy
Week 0 Week 48 Change (week 48–week 0) P value (H0: 0)
hs-CRP (mg/l) 2.0 (1.0–4.3) 3.0 (1.5–6.1) 0.6 (0.7 to 3.6) 0.01
IL-6 (pg/ml) 1.6 (0.9–2.7) 1.3 (0.7–2.1) 0.2 (0.9 to 0.4) 0.01
TNFR1 (pg/ml) 1,279 (1,109–1,573) 1,173 (992–1,388) 109 (387 to 40) 0.0001
TNFR2 (pg/ml) 4,414 (3,550–6,300) 2,983 (2,310–3,795) 1,390 (2,932 to 479) 0.0001
Data are median (interquartile range).
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association was lost after mutual adjust-
ment for other inﬂammatory cytokines or
measuresofadiposity(8,9,18).Wefound
that higher concentrations of sTNFR1
and sTNFR2 measured 48 weeks after
ART initiation were associated with inci-
dent diabetes, independent of BMI, sug-
gesting that TNF- activity in HIV-
infectedindividualsmaycontributetothe
pathogenesis of diabetes. It is not known
whether the origin of TNF- is the adi-
pose tissue, infected lymphocytes, or
other cell types, but this is an important
area for further inquiry.
Although all subjects were normogly-
cemicbeforeARTinitiation,subjectswho
were to develop diabetes already had sig-
niﬁcantly higher glucose concentrations
at 48 weeks after ART initiation, although
withinthenondiabeticrange.Afterwead-
justed for glucose levels at 48 weeks, the
associations between markers of TNF-
activity were attenuated, but higher levels
of sTNFR1 remained associated with in-
cident diabetes. These ﬁndings may sug-
gest that the effect of TNF- activity on
diabetes risk is present early on in the
pathogenesis of diabetes among HIV-
infectedindividualstreatedwithARTand
adjustment for glucose concentrations at
48 weeks obscured the early effect.
Whether this effect is mediated by in-
creased insulin resistance or a decline in
-cell function is unclear. A prospective
study examining inﬂammatory and insu-
lin resistance markers at earlier time
points after ART initiation would be
necessary to further investigate the
mechanisms.
Without adjustment for week 48 glu-
cose levels, we found that higher concen-
trations of hs-CRP at 48 weeks after ART
initiation were associated with incident
diabetes.hs-CRPhasbeenassociatedwith
incident diabetes in the general popula-
tion (7), but this association is partially
explained by excess adiposity (19). Evi-
dence against a causal effect of hs-CRP on
diabetes risk is derived from a Mendelian
randomization study, which found no as-
sociation between haplotypes associated
with higher hs-CRP concentrations and
diabetes risk (20). In our study, after ad-
justment for 48-week glucose values, the
associationbetween48-weekhs-CRPand
incident diabetes was no longer present,
suggesting that hs-CRP may be an early
marker of diabetes risk in HIV-infected
patients starting ART. Importantly, hs-
CRP is associated with other adverse out-
comesinHIV-infectedpatients,including
myocardial infarction (21) and all-cause
mortality (22). Whether therapies aimed
to decrease hs-CRP will improve out-
comes in HIV-infected individuals is
unknown.
Modern ART is very effective in sup-
pressing HIV replication. However, in all
studies of patients initiating ART, there is
a subset in whom HIV is not suppressed
to undetectable levels. Six subjects in the
study had viral RNA 400 copies/ml at
48 weeks. In a sensitivity analysis, we ex-
cluded those who had uncontrolled HIV
infection and found similar association
between inﬂammatory markers and inci-
dent diabetes. Although not nominally
statistically signiﬁcant, this analysis sug-
gests that our ﬁndings were not inﬂu-
enced by a small number of subjects with
uncontrolled HIV.
Ourstudyhadseverallimitationsthat
should be noted. Our sample size was
small, and, as a result, the effect estimates
were imprecise. Larger, conﬁrmatory
studies should be performed to better es-
timate the association between inﬂamma-
tion and diabetes in HIV-infected
individuals initiating ART. A larger study
wouldalsohavesufﬁcientpowertodeter-
mine whether the association between in-
ﬂammation and diabetes in HIV-infected
individuals differs by sex. Second, we ex-
amined only four different inﬂammatory
markers. Studies in the general popula-
tion have shown that other markers may
be associated with diabetes, such as IL-18
(23). Third, without an otherwise similar
HIV-uninfected control group, it is difﬁ-
cult to interpret the absolute levels of in-
ﬂammatorymarkersinourstudy.Finally,
family history of diabetes was not avail-
able in our dataset, and therefore we were
unable to adjust for this factor. However,
in the Multi-Ethnic Study of Atheroscle-
rosis (MESA) study, the inclusion of fam-
ily history did not alter the relationship
between inﬂammation and diabetes (19).
In summary, we found that inﬂam-
matory markers, particularly those asso-
ciatedwithTNF-activity,48weeksafter
ART initiation were associated incident
diabetes. Chronic inﬂammation among
HIV-infected individuals, even those re-
ceivingeffectiveantiretroviraltherapyhas
Table 3—Relationship between inﬂammatory marker level 48 weeks after initiation of ART
and incident diabetes in HIV-infected persons, with and without additional adjustment for
week 48 glucose levels
Marker
Model excluding week 48
glucose
Model including week 48
glucose
hs-CRP
Quartile 1 Referent Referent
Quartile 2 1.09 (0.19–6.36) 0.65 (0.09–4.69)
Quartile 3 2.62 (0.51–13.5) 1.88 (0.28–12.8)
Quartile 4 4.87 (0.87–27.2) 2.52 (0.36–17.6)
P value, test for trend 0.05 0.18
IL-6
Quartile 1 Referent Referent
Quartile 2 1.38 (0.29–6.54) 1.52 (0.21–10.9)
Quartile 3 3.94 (0.83–18.6) 3.34 (0.53–21.1)
Quartile 4 1.62 (0.31–8.47) 1.39 (0.23–8.28)
P value, test for trend 0.24 0.94
TNFR1
Quartile 1 Referent Referent
Quartile 2 5.36 (0.77–37.5) 2.88 (0.34–24.5)
Quartile 3 14.0 (1.37–143) 6.09 (0.61–60.8)
Quartile 4 39.4 (2.17–716) 23.2 (1.28–423)
P value, test for trend 0.01 0.03
TNFR2
Quartile 1 Referent Referent
Quartile 2 2.64 (0.56–12.5) 1.49 (0.25–8.95)
Quartile 3 2.38 (0.43–13.1) 1.01 (0.12–8.31)
Quartile 4 7.39 (1.18–46.4) 4.63 (0.60–35.8)
P value, test for trend 0.04 0.27
Data are odds ratio (95% CI) vs. quartile 1. All models also include age, natural log of baseline marker level,
BMI at week 48, CD4 200 at week 48, and IDV use through week 48.
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contributortothedevelopmentofcomor-
bid conditions. Our ﬁndings suggest that
inﬂammation contributes to the patho-
genesis of diabetes among treated HIV-
infected individuals. The discovery of
antiretroviral medication that suppresses
inﬂammation in addition to HIV repli-
cation or adjunctive therapy targeting
uncontrolled inﬂammation may be im-
portant in the prevention of comorbid
conditions associated with chronic HIV
infection, such as diabetes.
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